Non-cytotoxic protein conjugates
View Patent ↗The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described.
1. A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising:
(i) a galanin Targeting Moiety (TM),
wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell;
(ii) a non-cytotoxic protease or a protease fragment thereof,
wherein the protease or protease fragment cleaves a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell; and
(iii) a Translocation Domain,
wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell.
2. The non-cytotoxic conjugate of claim 1 , wherein the non-cytotoxic protease is selected from a clostridial neurotoxin, or an IgA protease.
3. The non-cytotoxic conjugate of claim 1 , wherein the Translocation Domain is a botulinum H N domain.
4. The non-cytotoxic conjugate of claim 1 , wherein the receptor is a GALR1 and/or a GALR2 receptor.
5. The non-cytotoxic conjugate of claim 1 , wherein the galanin TM comprises an amino acid sequence having at least 70% or at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 101 or SEQ ID NO: 102, or a fragment or variant thereof.
6. The non-cytotoxic conjugate of claim 1 , wherein the galanin TM comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:101 or SEQ ID NO: 102 or a fragment or variant thereof.
7. The non-cytotoxic conjugate of claim 1 , wherein the galanin TM comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:101 or SEQ ID NO: 102, or a fragment or variant thereof.
8. The non-cytotoxic conjugate of claim 1 , wherein the galanin TM comprises the amino acid sequence set forth in SEQ ID NO:101 or SEQ ID NO: 102.
9. The non-cytotoxic conjugate of claim 1 , wherein the nociceptive sensory afferent cell is a primary nociceptive sensory afferent cell.
10. The non-cytotoxic conjugate of claim 1 , wherein said conjugate comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 105 or SEQ ID NO: 106.
11. A pharmaceutical composition, comprising a conjugate according to claim 1 , and a pharmaceutically acceptable carrier.
12. A method for treating or ameliorating pain in a subject, comprising administering to said subject a therapeutically effective amount of a conjugate according to claim 1 , thereby treating or ameliorating pain in the subject.
13. The method according to claim 12 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.
14. A method for treating or ameliorating pain in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 11 , thereby treating or ameliorating pain in the subject.
15. The method according to claim 14 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.